Ambrisentan is under clinical development by Noorik Biopharmaceuticals and currently in Phase II for Hepatorenal Syndrome. According to GlobalData, Phase II drugs for Hepatorenal Syndrome have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ambrisentan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ambrisentan overview

Ambrisentan (N-003) was under development  for treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was administered through intravenous and oral route as solution. The drug candidate acts by targeting vasoconstrictor peptides.

It was also under development for the prevention of portal hypertension, delayed graft function (DGF), hepatorenal syndrome (HRS).

Noorik Biopharmaceuticals overview

Noorik Biopharmaceuticals (Noorik) is a drug development company that discovers and develops drug candidates for the treatment of renal orphan diseases through drug re-profiling. The company’s lead product candidate N-003 is a drug repurposing project. Noorik is currently being developed, N-003 as a first line therapy for two orphan renal indications which include delayed graft function (DGF) and hepatorenal syndrome (HRS). The company partner with other biotechnological companies for the development of therapy for prevention and treatment of acute renal failure. Noorik is headquartered in Basel, Switzerland. th

For a complete picture of Ambrisentan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.